Development and Dissemination of Clinical CEST MRI Acquisition and Analysis Methods for Cancer Imaging Applications

本研究计划将继续我们的化学交换饱和转移（CEST）MRI的发展 用于癌症患者成像的采集和分析方法。使用外源性造影剂的AcidoCEST MRI 试剂是该技术的创新变体，可测量实体瘤中的细胞外pH值。我们还 开发了一种非常创新的方法，该方法可采集具有多个功率的内源性CEST MR图像， 其可以测量内源性蛋白质的化学交换速率， 博士我们将通过加快成像速度，减少和 消除由于患者运动引起的并发症，消除由脂肪信号引起的并发症， 到3D成像方法。我们还将改进CEST对比度所需的图像分析方法， 内源性蛋白质和外源性造影剂。 我们的研究具有很强的影响力，因为acidoCEST MRI可以跟踪肿瘤酸中毒的变化， 用于乳腺癌和头颈癌患者的化疗和放化疗。 内源性CEST MRI可提高脑肿瘤复发与假性进展的诊断， 肺癌与肺部感染的评估。我们将用我们的内源性和外源性药物进行临床研究， CEST MRI方法用于对患有脑癌、乳腺癌、肺癌和头颈癌的患者进行成像。 为了扩大我们研究的影响，我们将开发CEST MRI采集方法的版本， MD安德森的13个西门子硬件平台和软件操作系统的许多版本 癌症中心我们还将为MD的许多研究人员开发用户友好的CEST分析方法 安德森。我们将利用我们独特的研究环境和专业知识与机构内传播 通过与其他CEST共享这些获取和分析工具，提供机构间传播 MRI研究人员。我们将与NIST合作提供第一个能够标准化的CEST MRI体模 开发和实施机构内和机构间CEST MRI方法。 我们的优秀研究人员团队包括CEST饱和度方法、CEST MR图像 分析，临床造影剂，快速MRI采集方法，高场7T MRI，临床放射学，生物统计学， 组织病理学和肿瘤学。基于我们在临床CEST MRI方面的专业知识和多年的生产力， 开发了一种特殊的研究方法。作为世界上最大的癌症中心和健康目的地， MD安德森癌症中心的患者群体为我们的研究提供了非常强大的机构支持。 临床研究。

This research plan will continue our development of Chemical Exchange Saturation Transfer (CEST) MRI acquisition and analysis methods for imaging patients with cancer. AcidoCEST MRI with an exogenous contrast agent is an innovative variation of this technique that measures extracellular pH in solid tumors. We have also developed an exceptionally innovative method that acquires endogenous CEST MR images with multiple powers, which can measure the chemical exchange rate of endogenous proteins that can assess relative differences in pH. We will improve our CEST MRI acquisition methods by accelerating the imaging speed, reducing and eliminating complications due to patient motion, eliminating complications caused by fat signal, and expanding to 3D imaging methods. We will also improve image analysis methods that are required for CEST contrast from endogenous proteins and exogenous contrast agents. Our research has strong impact because acidoCEST MRI can track changes in tumor acidosis in response to chemotherapy and chemoradiation therapy in patients who have breast cancer and head & neck cancer. Endogenous CEST MRI can improve the diagnoses of brain tumor recurrence vs. pseudoprogression, and evaluations of lung cancer vs. lung infection. We will perform clinical studies with our endogenous and exogenous CEST MRI methods to image patients with brain, breast, lung, and head & neck cancers. To amplify the impact of our research, we will develop versions of our CEST MRI acquisition methods for the many versions of the 13 Siemens hardware platforms and software operating systems at the MD Anderson Cancer Center. We will also develop user-friendly CEST analysis methods for many researchers at MD Anderson. We will leverage our unique research environment and expertise with intra-institutional dissemination to provide inter-institutional dissemination, by sharing share these acquisition and analysis tools with other CEST MRI researchers. We will collaborate with NIST to provide the first CEST MRI phantom that can standardize the development and implementation of intra- and inter-institutional CEST MRI methods. Our team of outstanding investigators includes experts in CEST saturation methods, CEST MR image analysis, clinical contrast agents, rapid MRI acquisition methods, high field 7T MRI, clinical radiology, biostatistics, histopathology and oncology. Based on our expertise and years of productivity in clinical CEST MRI, we have developed an exceptional research approach. As the world's largest cancer center and a health destination, the MD Anderson Cancer Center has the patient population that provides very strong institutional support for our clinical studies.